DE07776925T8 - Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums - Google Patents

Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums Download PDF

Info

Publication number
DE07776925T8
DE07776925T8 DE07776925T DE07776925T DE07776925T8 DE 07776925 T8 DE07776925 T8 DE 07776925T8 DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T8 DE07776925 T8 DE 07776925T8
Authority
DE
Germany
Prior art keywords
storage
crystalline form
atorvastatin calcium
stable atorvastatin
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE07776925T
Other languages
English (en)
Other versions
DE07776925T1 (de
Inventor
Judith Aronhime
Ramy Lindor-Hadas
Valerie Niddam-Hildesheim
Shlomit Wizel
Revital Lifshitz-Liron
Michael Pinchasov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE07776925T1 publication Critical patent/DE07776925T1/de
Application granted granted Critical
Publication of DE07776925T8 publication Critical patent/DE07776925T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE07776925T 2006-05-09 2007-05-08 Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums Active DE07776925T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/431,183 US20070265456A1 (en) 2006-05-09 2006-05-09 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20060431183 2006-05-09
PCT/US2007/011236 WO2007133597A1 (en) 2006-05-09 2007-05-08 Crystalline form of atorvastatin calcium stable after storage

Publications (2)

Publication Number Publication Date
DE07776925T1 DE07776925T1 (de) 2008-07-03
DE07776925T8 true DE07776925T8 (de) 2009-04-30

Family

ID=38512661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE07776925T Active DE07776925T8 (de) 2006-05-09 2007-05-08 Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums

Country Status (11)

Country Link
US (1) US20070265456A1 (de)
EP (1) EP2024331A1 (de)
JP (2) JP2009500429A (de)
KR (1) KR20080015510A (de)
CN (1) CN101437791A (de)
BR (1) BRPI0702876A2 (de)
CA (1) CA2649708A1 (de)
DE (1) DE07776925T8 (de)
ES (1) ES2312307T1 (de)
IL (1) IL194876A0 (de)
WO (1) WO2007133597A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS100003A (en) * 2001-06-29 2007-02-05 Warner-Lambert Company, Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EE03606B1 (et) * 1995-07-17 2002-02-15 Warner-Lambert Company Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
EP1480950A4 (de) * 2002-02-15 2005-05-18 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
US7122681B2 (en) * 2002-02-19 2006-10-17 Teva Pharmaceutical Industries, Ltd. Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
RU2412191C2 (ru) * 2004-07-16 2011-02-20 Лек Фармасьютиклз Д.Д. Продукты окислительной деструкции кальций аторвастатина
DE05774589T1 (de) * 2004-07-22 2007-08-09 Teva Pharmaceutical Industries Ltd. Neue kristallformen von atorvastatin-hemi-calcium und verfahren zu deren herstellung
MX2007003652A (es) * 2004-09-28 2009-02-16 Teva Pharma Proceso para preparar formas de calcio de atorvastatina sustancialmente libre de impurezas.

Also Published As

Publication number Publication date
CN101437791A (zh) 2009-05-20
WO2007133597A9 (en) 2008-01-24
DE07776925T1 (de) 2008-07-03
EP2024331A1 (de) 2009-02-18
JP2009500429A (ja) 2009-01-08
ES2312307T1 (es) 2009-03-01
JP2007302665A (ja) 2007-11-22
US20070265456A1 (en) 2007-11-15
CA2649708A1 (en) 2007-11-22
IL194876A0 (en) 2009-08-03
KR20080015510A (ko) 2008-02-19
WO2007133597A1 (en) 2007-11-22
BRPI0702876A2 (pt) 2011-03-15

Similar Documents

Publication Publication Date Title
IL295518B1 (en) Heterocyclic compounds used as pdk1 inhibitors
NO345061B1 (no) Anvendelse av DPP-IV inhibitorer
DK2379600T4 (da) Antistoffer mod tissue factor pathway inhibitor
EP2330894A4 (de) Zusammensetzungen mit 6-aminohexansäurederivaten als hdac-hemmer
DK2004248T3 (da) Bio-opløsende saltcoatings af implantater til beskyttelse mod organiske urenheder
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
EP2325181A4 (de) Stat3-inhibitor, der als wirkstoff ein chinolincarbonsäureamidderivat enthält
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
CR10400A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta -hidroxiesteroide deshidrogenasa 1
IL200617A0 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
DK2010496T3 (da) 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
EP2192838A4 (de) Heterocyclische nekroptose-hemmer
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
BRPI0905680A2 (pt) "composição farmacêutica de uma composição farmacêutica"
EP2336123A4 (de) Heterozyklische verbindung als proteinkinasehemmer
ATE509925T1 (de) Substituierte bicyclocarbonsäureamidverbindungen
EP2341773A4 (de) Pharmazeutische zusammensetzungen aus atorvastatin
BRPI0816221A8 (pt) forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
DE07776925T8 (de) Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums
ITFI20070288A1 (it) Inibitori delle deacetilasi istoniche
EP1986997A4 (de) Neue kristalline form von atorvastatin-hemicalcium
IL195061A0 (en) Crystalline forms of atorvastatin
BRPI0913347A2 (pt) modificações estáveis de cristais de dopc
EP2113251A4 (de) Verwendung von verbindungen als helicobacter-flavodoxin-hemmer
IS8607A (is) Stöðugar atorvastatin samsetningar

Legal Events

Date Code Title Description
8596 Reprint of erroneous front page